
Japan’s Ono Pharmaceutical (TYO: 4528) today announced that it has entered into an exclusive license agreement with US biopharma Biohaven (NYSE: BHVN) for the development and commercialization of Biohaven’s IgG degrader portfolio, including BHV-1300, BHV-1310, and BHV-1320, in Japan, South Korea, Taiwan and ASEAN countries.
The IgG degrader portfolio consists of novel small-molecule therapeutics generated from Biohaven's proprietary MoDE extracellular protein degrader platform. The portfolio leverages endogenous protein degradation mechanisms to selectively eliminate the major IgG subclasses, IgG1, IgG2, and IgG4, of disease-causing autoantibodies associated with autoimmune diseases and is being developed as a potential innovative therapeutic approach targeting the underlying cause of autoimmune diseases. BHV-1300, the most advanced program in the portfolio, is currently in global Phase III development for Graves' disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze